The impact of regulatory restrictions on the use of valproic acid in women of childbearing age: An Italian study.

Lidia Di VitoStefania MazzoniLaura Maria Beatrice BelottiElisabetta PoluzziElisa BaldinCorrado ZenesiniFrancesca BisulliPaolo TinuperBarbara Mostacci

Published in: Epilepsia (2023)

After the regulatory restrictions, an overall significant decline in the use of VPA in WOCA was observed in ERR. The second restriction has been effective in consolidating the prescription trend. However, VPA appears to be still a commonly used drug in WOCA when other ASMs have failed.

Keyphrases

transcription factor
polycystic ovary syndrome
type diabetes
pregnancy outcomes
pregnant women
adverse drug